Vericiguat
Vericiguat is used to treat
[A] Myocardial Infarction[B] Pulmonary arterial hypertension
[C] HOCM
[D] Heart Failure
What is the mechanism of action of Vericiguat ?
[A] Inhibit endothelin-1
[B] Inhibit Phosphodiesterase-4
[C] Neprilysin Inhibitor
[D] Soluble guanylate cyclase stimulator
Vericiguat
- Vericiguat stimulates soluble guanylate cyclase that activates the cGMP pathway independent of nitric oxide involvement.
- It also sensitizes soluble guanylate cyclase to nitric oxide by stabilizing nitric oxide binding to the binding site.
- Vericiguat restores the cyclic guanosine monophosphate under low nitric oxide conditions and oxidative stress.
According to ACC/AHA 2022 guidelines
Heart failure (HF) has been classified as
- Stage A – At risk of HF
- Stage B – Pre-HF
- Stage C – Symptomatic HF
- Stage D – Advanced HF
Vericiguat should be considered for patients with
Stage C HFrEF – (Structural heart disease with current or previous symptoms of HF).
According to phase III of the VICTORIA Heart Failure with Reduced Ejection Fraction study, the dose of vericiguat can be increased from 2.5 mg to 10 mg depending on patient response.
